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Functioning can be defined as the ability to perform daily activities, and to main-
tain interpersonal relationships and work capacity/productivity. Major Depressive 
Disorder (MDD) is associated with substantial impairment in functioning. The 
study examined associations between various measures of functioning (patient 
assessment) and MDD symptoms (clinician assessment). A major challenge was 
to ensure MDD patient compliance with regular self-assessments and retention in 
a long-term study.Objectives: The purpose of the Direct to Patient Contact (DPC) 
approach was to maximize patient compliance to Patient Reported Outcomes 
(PRO) data collection and retention in a study conducted in real life settings over 
a two-year follow-up period. MethOds: This was an international, multicentric, 
observational, prospective longitudinal cohort study involving 1,500 MDD patients 
followed-up for two years in five European countries. Patients were recruited by 
General Practitioners or psychiatrists and data collected using a hybrid method: 
clinical data by physicians and PRO data self-assessment by patients. DPC actions 
included PRO questionnaire shipments to patients at five time points, followed 
by phone reminder contacts for non-returned questionnaires. Results: 1,450 
patients were included in the study, 97.8% of whom agreed to be contacted directly 
by DPC staff. Overall, 71.7% of patients were reached by phone and 75.6% of PRO 
questionnaires were returned; the questionnaire completion rate reached 95.3%. 
79.6% of patients remained until study end, 0.1% died, 3.5% voluntarily with-
drew from the study and 16.7% were withdrawn for other reasons. There were 
no patients lost to follow up. cOnclusiOns: This study demonstrates that the 
use of DPC in a MDD population, likely to be study non-compliant/unresponsive, 
produced excellent long-term response rates. It minimized voluntary patient 
drop-outs and lost to follow up rates, and ensured an enhanced data collection of 
self-assessed PROs, thus improved reliability of study outcomes.
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Objectives: Excess chin and neck fat adversely affects facial appearance, producing 
measureable negative impacts on psychological health and psychosocial function. 
The Patient-Reported Submental Fat Impact Scale (PR-SMFIS) is a patient-reported 
outcome (PRO) measure developed and validated to assess submental fat (SMF)-
associated psychological impact and its improvement associated with the reduction 
of SMF with deoxycholic acid (DCA) injection (ATX-101) as an injectable treatment 
for SMF. MethOds: Scale development and validation followed global regulatory 
guidelines and industry best practices. A conceptual model and draft response 
items were developed based on literature review, key opinion leader interviews, and 
patient concept elicitation interviews. The resulting 6-item scale assesses negative 
psychological impact of SMF on emotional perceptions (happiness, self-conscious-
ness, bothersomeness, and embarrassment) and visual perceptions (looking older 
and overweight). Items are rated on an 11-point scale (0 = no impact, 10 = extreme 
negative impact); the total scale score is the average response. Six clinical trials of 
ATX-101 for SMF treatment provide assessments of reliability, construct validity, 
sensitivity to change, and score interpretation. PR-SMFIS validity was assessed using 
two generic measures of psychological impact, the Derriford Appearance Scale-24 
(DAS-24) and Body Image Quality of Life Inventory (BIQLI). Results: The PR-SMFIS 
demonstrated high test-retest reliability (Intra-class correlation = 0.75), internal 
consistency (Cronbach’s alpha › 0.92), external validity against the DAS-24 (r = 0.57) 
and BIQLI (r = -0.3), and patient SMF ratings (r = 0.49 to 0.75). SMF treatment pro-
duced large effect sizes (Cohen ES = -2) consistent with effect sizes for clinician and 
patient ratings, and objective measures of SMF reduction. cOnclusiOns: These 
results confirm that PR-SMFIS is a content-valid PRO instrument with robust reli-
ability and validity for SMF psychological impact assessment.
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Objectives: To determine which patient-reported outcome (PRO) and car-
egiver quality of life tools were used in studies on dementia published in 
2014. MethOds: An evidence surveillance process was established based on a 
systematic search of PubMed, incorporating all studies published from 2010 and 
updated weekly, with a final search on 18 May 2015. Abstracts identified by the 
search that reported humanistic burden outcomes in dementia were identified. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified, where 
possible, from the abstract alone. Results: Of 1,980 articles published in 2014 
identified by the search for PROs and quality of life, 32 were relevant to patients 
and/or caregivers of adults with dementia, cognitive impairment or memory loss. 
The PRO used was not specified in 17 abstracts, but 19 different PRO or caregiver-
reported instruments were cited in the remaining 15 abstracts. Dementia-specific 
instruments included the Quality of life-Alzheimer’s disease (QoL-AD), used in 6 
studies, and the Alzheimer’s Disease Assessment Scale - Cognition (ADAS-Cog), the 
Five-Cog test, the Metamemory in Adulthood Questionnaire and the Mild Cognitive 
Impairment Questionnaire (MCQ), used in 1 study each. Despite the substantial 
burden on caregivers, only 8 studies reported outcomes related to the humanistic 
burden in this population. Instruments used in caregivers included generic utility 
measures, the QOL-AD, and the Zarit Burden Interview, but were not specified in 
5 abstracts. Utilities were measured in only 3 studies, with Short Form (12 or 36) 
used in all 3 studies and EQ-5D in one. Depression was assessed in 2 studies of 
lowed by the UK (13), the Netherlands (7) and Germany (4). Despite the high societal 
costs associated with mental illness, this was generally under-reported, with just 
26 of the 76 articles reporting indirect social, productivity, informal care or criminal 
justice costs. In comparison, direct costs were evaluated in 48 articles and healthcare 
resource use in 38 articles. Indirect costs were reported in 6 of the 7 studies from 
the Netherlands, compared with 4 of the 13 UK studies and 6 of the 31 USA studies. 
Caregiver burden was assessed in just 3 studies, one each on dementia, autism and 
depression. cOnclusiOns: Recent research on economic burden in mental health 
disorders has focused disproportionately on the management of substance abuse 
and on direct costs or healthcare resource use. Up-to-date data on indirect costs 
from other chronic mental disorders remains sparse.
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Objectives: Some studies on the effects of adherence and persistence to antipsy-
chotics on healthcare use suggested negative associations between adherence and 
resource utilization, whereas several other studies suggested positive associations 
or no associations. This study aims to estimate the impacts of adherence and per-
sistence to atypical antipsychotics on costs and hospitalization by reducing possible 
endogeneity. MethOds: To examine the effects of adherence (proportion of days 
covered) and persistence (time-to-discontinuation) to atypical antipsychotics in 
the first year following the initiation of atypical antipsychotic therapy on costs and 
hospitalization in the second year, we carried out retrospective analysis of 2007-2013 
Humana claims data. Individuals in the databases with a diagnosis of schizophrenia 
or bipolar disorder at any time and had a prescription for non-injectable atypical 
antipsychotics were identified and selected. Instrumental variable (IV) regressions 
using reimbursement rate and mail order as IVs were conducted to correct poten-
tial endogeneity. Results: Being adherent was associated with decreased total 
costs by US$19,497 (p< 0.05), increased medication costs by US$8,194 (p< 0.001), 
decreased medical services costs by US$27,664 (p< 0.001), and reduced hospitaliza-
tion risk by 27% (p< 0.001). Being persistent was associated with decreased indi-
vidual total costs by US$23,927 (p< 0.05), increased medication costs by US$10,278 
(p< 0.001), and decreased medical services costs by US$34,178 (p< 0.001). We could 
not identify significant association between persistence and the risk of hospitaliza-
tion. cOnclusiOns: Good adherence and persistence to atypical antipsychotics 
lead to lower total costs than poor adherence and persistence. Efforts should be 
made to improve adherence and persistence.
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bAckgROund: Adherence to antidepressant treatment is demanded for both 
clinical and economic effectiveness in treated depression. The Lam Employment 
Absence and Productivity Scale (LEAPS) was acquired, re-validated and tested 
in blind randomization with Thai Depression Inventory (TDI). Objectives: 
To assess effects of antidepressant-based treatment among ambulatory Thai 
depressed patients after 3 months completed adherence to treatment with TDI 
and LEAPS. MethOds: Thai depressed patients in public hospital under antide-
pressant-based treatment were follow-up, 50 were completed adherence for 3 
months. The LEAPS and TDI were assessed independently by both psychiatrists 
and hospital pharmacist. Apparent economic impact of treatment was computed 
based on work-absence employed the minimum daily wage-average of workers 
of the region. Results: 107 depressed patients of 26 Men/81 Women, mean(SD) 
age of 41.9(12.0) years, 34(31.8%) had physical illnesses. 25 patients (23.4%) were 
treated by antidepressant only, 82(76.6%) were treated by anti-depressant plus 
other psychotropics. The Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclics 
Antidepressant (TCAs) and others were prescribed at 55(51.4%), 41 (38.3%) 11 
(10.3%). After 3 months follow-up treatment, significant reduction of both TDI 
and LEAPS with mean(SD) score observed from 50 patients with completed adher-
ence to treatment where depressed symptoms score (assessed with TDI) reduced 
from 34.06(13.5) to 15.9(12.9) (p< 0.05) and LEAPS from 18.16(7.3) to 6.9(6.4) (p< 0.05) 
respectively. Both TDI and LEAPS were well correlated (r= 0.84, p< 0.05). During 3 
months treatment period, work absence was reduced from 86% to 36%. Overall eco-
nomic effectiveness of the adherence to treatment among 50 patients treated with 
anti-depressant-based, unless otherwise economic gains in terms of increased 
productivity could be anticipated from 1.4 to 1.7 Mio THB for the complete adher-
ence to treatment group. cOnclusiOns: Completed adherence antidepressant-
based treatment is effective to reduce clinical symptoms of depression with 
reduction of work absence. The LEAPS and TDI are well correlated suggesting 
further evaluation for its benefits in larger depressed working population.
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